Table 2.
Schedule of research visits
| Data Sources | Pre-Baseline | Baseline | Wk0 | Wk4 | Wk8 | Wk12 | Wk24 | Final Tx Wk | FU Wk4 |
FU Wk12 |
FU Wk24 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood Tests | |||||||||||
| HCV Viral Load | X | X | X | X | X | X | X | X | X | ||
| Resistance Tests (NS3/4A, NS5A, NS5B Assays) |
X | X | X | X | X | X | |||||
| Other Clinical Measures | |||||||||||
| Urine Toxicology (amphetamine, benzos, cocaine, methadone, opiates, oxycodone) | X | X | X | X | X | X | X | X | X | ||
| Methadone dose | X | X | X | X | X | X | |||||
| Chart Abstraction | X | X | |||||||||
| Blister Pack | X | X | X | X | X | ||||||
| Questionnaires (ACASI) | |||||||||||
| Demographics | X | ||||||||||
| Adherence [32, 66, 67] | X | X | X | X | X | ||||||
| ACTG for Interferon if used [31] | X | X | X | X | X | ||||||
| Awareness of Viral Load questions | X | X | X | X | X | X | X | ||||
| Quality of Life: EQ-5D-3 L [38, 68], HCV QoL [69, 70] | X | X | X | X | X | X | X | X | |||
| Depression: BDI-II [71, 72] | X | X | X | X | X | X | X | X | |||
| Healthcare Service Utilization (NMOS) [73] | X | X | X | X | X | X | X | X | |||
| Alcohol: AUDIT [74] | X | X | X | X | X | X | X | X | |||
| Drug and Alochol Use: ASI-Lite [75, 76] | X | X | X | X | X | X | X | X | |||
| Tobacco Questionnaire [77] | X | X | |||||||||
| Social Support: Norbeck Social Support Questionnaire [78], MOS [79] | X | X | X | X | X | X | |||||
| IMB Questions [80, 81] | X | X | |||||||||
| HCV Beliefs | X | X | |||||||||
| Common Sense Model Questions [82] | X | X | |||||||||
| Psychiatric comorbidities: MINI [83] | X | ||||||||||
| Trust in physician [84] | X | ||||||||||
| Distrust in Health Care System [85] | X | ||||||||||
| Trust in Health Care Provider [86] | X | ||||||||||
| Subjective Opiate Withdrawal Scale [87] | X | X | X | X | X | X | X | X | |||
| Side Effects Survey | X | X | X | X | X | X | |||||